
Proteomics
We move Omics into clinical applications through the implementation of targeted proteomics technology. Collaborating with renowned academic partners, we excel in translating biomarkers into clinical contexts. Our expertise lies in crafting multiplexed targeted proteomic biomarker panels, enabling high-throughput validation of potential biomarkers.
​
Our approach to biomarker discovery is structured in two phases. Phase 1 involves a comprehensive untargeted proteomic exploration, followed by Phase 2, which employs a higher throughput targeted proteomic confirmation process. To enhance biomarker discovery, we employ multiplex biomarker panels integrated with machine learning, pushing the boundaries of precision and efficiency in biomarker identification and validation. Contact us today to begin exploring how we can enhance your clinical analysis.

Cardiac Panels
We have a range of assays to diagnose and monitor cardiac disease, including our groundbreaking advancement in the detection and monitoring of Hypertrophic cardiomyopathy (HCM).

Neurodegenerative panels
Following years of academic innovation, we have developed several research tests for the monitoring and diagnosis of neurodegenerative diseases, such as Parkinson's and Alzheimer's disease.​
